Evidence builds for early oseltamivir administration in pediatric influenza B pneumonia

  • Dai Z & al.
  • Pediatr Infect Dis J
  • 1 Feb 2020

  • curated by Liz Scherer
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Early oseltamivir administration (

Why this matters

  • Oseltamivir administration should be considered for reducing pneumonia complications in patients age 
  • Consult ECDC guidance on antiviral usage in influenza.

Key results

  • 137 children; mean age, 4.39 years (standard deviation, +3.5; range, 1 month-15 years).
  • 35.0% were 2-5 years old, and 32.1%, were 5-9 years old.
  • 39.4% (54) had underlying pneumonia.
  • Clinical and laboratory characteristics associated with pneumonia:
    • Frequent cough: 90.7% (P=.001),
    • C-reactive protein: 18.1±18.0 (P=.004).
  • Patients ages 0-4 years (P=.002) and 5-9 years (P=.014) were most likely to receive oseltamivir
  • No differences noted by sex, age, underlying conditions, preadmission antibiotics, or recent influenza vaccine receipt in patients with/without pneumonia.
  • Logistic regression associated pneumonia risk with: 
    • Early oseltamivir: OR, 0.108 (P=.000); and
    • Frequent cough: OR, 2.153 (P=.005).

Study design

  • Retrospective, observational study assessing clinical, laboratory findings linked to increased influenza B virus-associated pneumonia in hospitalized Chinese children, November 2017-April 2018
  • Funding: None disclosed.

Limitations

  • Retrospective, observational. 
  • Limited generalizability.